

## Disclosures

### Personal Commercial (13)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Akcea/Ionis	Research/Research Grants ‡ Prevalence and Prediction of Transthyretin Amyloidosis in Ambulatory Patients with Heart Failure with Preserved Ejection Fraction	Significant (>= \$5,000)	
Anylam	Research/Research Grants ‡ Prevalence and Prediction of Transthyretin Amyloidosis in Ambulatory Patients with Heart Failure with Preserved Ejection Fraction	Significant (>= \$5,000)	
Amgen Inc.	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Baim Institute for Clinical Research (non-profit) for Abbott	Other - Clinical Endpoint Committee for Abbott, Siemens and Beckman Coulter	Significant (>= \$5,000)	General Cardiology Heart Failure and Cardiomyopathies Valvular Heart Disease
Eko	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology Heart Failure and Cardiomyopathies
Eko	Ownership Interest/Partnership/Principal	Significant (>= \$5,000)	General Cardiology Heart Failure and Cardiomyopathies
Jana Care	Research/Research Grants ‡ Habits Heart Trial	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Merck & Co., Inc.	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
MGH Cardiology Board Review Book	Officer, Director, Trustee, or other Fiduciary Role	Modest (< \$5,000)	Other
Novartis Corporation	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Ortho Clinical	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Pfizer Inc	Research/Research Grants ‡ Prevalence and Prediction of Transthyretin Amyloidosis in Ambulatory Patients with Heart Failure with Preserved Ejection Fraction	Significant (>= \$5,000)	
Roche Diagnostics	Research/Research Grants ‡ ICON-HfpEF Development Program, PREFER-HF study	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

‡ Commercial Funding Source | ‡ Trial Name

## Agreement

Certified Education Attestation | Signed on 4/14/2022

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 4/14/2022

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>*

**Embargo** | Signed on 4/14/2022

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>*

**On-Going Obligation Agreement** | Signed on 4/14/2022

---

## **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.